IP Library Granted Patent US 9,371,281
Granted Patent B2
US 9,371,281 · App. 14/527,666 · Granted Jun 21, 2016

Indole derivatives as inhibitors of histone deacetylase

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,371,281
App. No.
14/527,666
Granted
Jun 21, 2016
Kind
B2
Abstract

Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.

Claims (90)

1. A compound of Formula Ia or IIa:

wherein:

R 1 is —C(O)NHOH;

X 2 is a bond, or alkylene; where the alkylene is optionally substituted with one, two, three, four, or five halo;

R 2 is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are optionally substituted with one, two, or three acyl, acylamino, acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, alkoxycarbonyl, amino, alkylamino, dialkylamino, alkylaminocarbonyl, dialkylaminocarbonyl, optionally substituted arylaminocarbonyl, optionally substituted heteroarylaminocarbonyl, carboxy, cyano, halo, haloalkoxy, or nitro;

R 3 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxy, alkoxy, or haloalkoxy;

R 4 is hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, hydroxy, alkoxy, haloalkoxy, or optionally substituted phenyl;

X 5 is a bond, alkylene, or alkenylene where the alkylene or alkenylene is optionally substituted with halo; and

R 5 is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are optionally substituted with one, two, or three acyl, acylamino, acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, alkoxycarbonyl, amino, alkylamino, dialkylamino, alkylaminocarbonyl, dialkylaminocarbonyl, optionally substituted arylaminocarbonyl, optionally substituted heteroarylaminocarbonyl, carboxy, cyano, halo, haloalkoxy, or nitro;

or a pharmaceutically acceptable salt thereof.

2. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

X 2 is a bond.

3. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

X 2 is alkylene.

4. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

X 2 is —CH 2 —, —CH 2 CH 2 —, —CH(CH 3 )—, or —(CH 2 ) 3 —.

5. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

X 2 is —CH 2 —.

6. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

R 2 is aryl where the aryl is optionally substituted with one, two, or three acyl, acylamino, acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, alkoxycarbonyl, amino, alkylamino, dialkylamino, alkylaminocarbonyl, dialkylaminocarbonyl, optionally substituted arylaminocarbonyl, optionally substituted heteroarylaminocarbonyl, carboxy, cyano, halo, haloalkoxy, or nitro.

7. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

R 2 is cyclohexyl, benzo[2,1,3]oxadiazol-5-yl, phenyl, naphth-2-yl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-(difluoromethoxy)-phenyl, 4-(trifluoromethoxy)-phenyl, 3-fluoro-4-methoxy-phenyl, piperidin-4-yl, or N-(t-butoxycarbonyl)piperidin-4-yl.

8. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

R 3 is hydrogen, alkyl, or substituted alkyl.

9. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

R 3 is hydrogen.

10. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

R 4 is alkyl or optionally substituted phenyl.

11. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

X 5 is alkylene.

12. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

R 5 is phenyl optionally substituted with one, two, or three acylamino, amino, halo, or nitro.

13. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

R 5 is 4-(t-butoxycarbonyl)piperazin-1-yl, phenyl, 4-aminophenyl, 4-(phenylcarbonylamino)-phenyl, 4-fluorophenyl, or 4-nitrophenyl.

14. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

R 3 is hydrogen;

X 2 is alkylene; and

R 2 is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are optionally substituted with one, two, or three alkyl, alkoxy, halo, or haloalkoxy.

15. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

R 3 is hydrogen;

X 2 is —CH 2 —; and

R 2 is aryl, cycloalkyl, heteroaryl, or heterocycloalkyl, where the aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are optionally substituted with one, two, or three alkyl, alkoxy, halo, or haloalkoxy.

16. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

R 3 is hydrogen;

X 2 is —CH 2 —; and

R 2 is aryl where the aryl is optionally substituted with one, two, or three acyl, acylamino, acyloxy, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkoxy, alkoxycarbonyl, amino, alkylamino, dialkylamino, alkylaminocarbonyl, dialkylaminocarbonyl, optionally substituted arylaminocarbonyl, optionally substituted heteroarylaminocarbonyl, carboxy, cyano, halo, haloalkoxy, or nitro.

17. The compound, or a pharmaceutically acceptable salt thereof, of claim 1 , wherein:

R 3 is hydrogen;

X 2 is —CH 2 —; and

R 2 is cyclohexyl, benzo[2,1,3]oxadiazol-5-yl, phenyl, naphth-2-yl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,5-dimethoxyphenyl, 3,4,5-trimethoxyphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-(difluoromethoxy)-phenyl, 4-(trifluoromethoxy)-phenyl, 3-fluoro-4-methoxy-phenyl, piperidin-4-yl, or N-(t-butoxycarbonyl)piperidin-4-yl.

18. The compound of claim 1 , wherein the compound is:

1-(3,4-dichloro-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(2-methyl-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(3,4,5-trimethoxy-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(3-fluoro-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(3-methyl-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(benzyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(3,5-dimethoxy-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(1-methyl-1-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(4-fluoro-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(2-fluoro-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(2-chloro-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(3-methoxy-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(naphth-2-ylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(3-phenylpropyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(cyclohexylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-[4-(trifluoromethoxy)-phenylmethyl]-1H-indole-6-carboxylic acid hydroxyamide;

1-(4-chloro-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(benzo[2,1,3]oxadiazol-5-ylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(4-methyl-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(3-fluoro-4-methoxy-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-[4-(difluoromethoxy)-phenylmethyl]-1H-indole-6-carboxylic acid hydroxyamide;

1-(4-methoxy-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(phenethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-(3-chloro-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

1-[N-(t-butoxycarbonyl)piperidin-4-ylmethyl]-1H-indole-6-carboxylic acid hydroxyamide; or

1-(piperidin-4-ylmethyl)-1H-indole-6-carboxylic acid hydroxyamide;

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 , wherein the compound is:

1-methyl-3-(4-nitro-phenylmethyl)-1H-indole-5-carboxylic acid hydroxyamide;

1-ethyl-3-(phenylmethyl)-1H-indole-5-carboxylic acid hydroxyamide;

1-methyl-3-[4-(phenylcarbonylamino)-phenylmethyl]-1H-indole-5-carboxylic acid hydroxyamide;

1-isopropyl-3-(phenylmethyl)-1H-indole-5-carboxylic acid hydroxyamide;

1-methyl-3-(4-amino-phenylmethyl)-1H-indole-5-carboxylic acid hydroxyamide;

1-methyl-3-(4-fluoro-phenylmethyl)-1H-indole-5-carboxylic acid hydroxyamide;

1-phenyl-3-(phenylmethyl)-1H-indole-5-carboxylic acid hydroxyamide; or

1-methyl-3-[4-(t-butoxycarbonyl)piperazin-1-ylmethyl]-1H-indole-5-carboxylic acid hydroxyamide;

or a pharmaceutically acceptable salt thereof.

20. The compound of claim 1 , wherein the compound is 1-(4-methoxy-phenylmethyl)-1H-indole-6-carboxylic acid hydroxyamide; or a pharmaceutically acceptable salt thereof.

21. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0368. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER AND CHANGE OF NAME. Recorded May 18, 2016
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 038742/0371 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY DATA PREVIOUSLY RECORDED ON REEL 036126 FRAME 0359. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded May 17, 2016
From: OXFORD AMHERST CORPORATION; PHARMACYCLICS, INC.
To: PHARMACYCLICS, INC.
Reel/Frame 038742/0064 →
MERGER Recorded Jul 16, 2015
From: OXFORD AMHERST CORPORATION
To: PHARMACYCLICS, INC.
Reel/Frame 036126/0359 →
MERGER AND CHANGE OF NAME Recorded Jul 16, 2015
From: PHARMACYCLICS, INC.; OXFORD AMHERST LLC
To: PHARMACYCLICS LLC
Reel/Frame 036126/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2014
From: BUGGY, JOSEPH J.; BALASUBRAMANIAN, SRIRAM; VERNER, ERIK; TAI, VINCENT W.F.; LEE, CHANG-SUN
To: PHARMACYCLICS, INC.
Reel/Frame 034105/0726 →